舒泰神(300204.SZ):STSA-1002注射液獲得Ib II期臨牀試驗研究初步結果
格隆匯5月28日丨舒泰神(300204.SZ)公佈,近日,STSA-1002注射液已結束針對急性呼吸窘迫綜合徵(ARDS)Ib/II期臨牀試驗入組,完成數據庫清理、盲態數據審核、揭盲,並收到頂線數據(ToplineData)初步統計分析結果。本次STSA-1002注射液(急性呼吸窘迫綜合徵適應症)獲得Ib/II期臨牀試驗研究初步結果不會對公司當前業績產生重大影響。
STSA-1002注射液在ARDS患者中開展了一項隨機、雙盲、安慰劑對照的Ib/II期臨牀試驗(組長單位中日友好醫院、主要研究者曹彬),試驗分為3組:試驗組1(低劑量組)、試驗組2(高劑量組)和對照組,以探索STSA-1002注射液的初步有效性和安全性。在本研究的給藥劑量和頻率下,STSA-1002注射液在ARDS患者中安全性、耐受性良好。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.